• The skin is our largest organ.

    The skin is unique in many ways, but no other organ is so visible and demands so much attention and care in both diseased and healthy states.

About us

Dermaliq Therapeutics, Inc., is a clinical stage pharmaceutical company with a therapeutic focus on dermatology, founded in 2021 through a spin-off from Novaliq GmbH.

Our mission is to develop a new generation of superior topical therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. Our unique “hyliQTM” technology is driving a growing product pipeline in key dermatological indications. The technology offers superior bioavailability and stability for many active ingredients combined with a cosmetic acceptability that was previously hard to achieve for topically applied drugs.

THERAPEUTIC FOCUS

Dermatology

Skin disorders and diseases are the fourth leading cause of nonfatal disease burden worldwide, underscoring the importance of dermatology in the field of global health. Skin conditions have significant impact on patients’ well-being, mental health, ability to function, and social participation.
Dermatological treatments are largely divided into external application of drugs (topical therapies), systemic therapies (oral administration or injections of drugs or biologics), physical therapies (for example, light and climate therapies), and laser or surgical therapies. Among these treatments, topical and localized delivery of active ingredients to the diseased skin is the preferred route of treatment in a majority of patients, reducing the risk of systemic side effects.

  • therapeutics focus
  • focus on disease

Technology

The evolutionary hyliQTM– technology

hyliQTM, the unique and proprietary technology owned by Dermaliq, is designed to provide cutaneous drug delivery with unmatched bioavailability for a wide range of pharmaceutical actives.

The technology enables the development of superior liquid therapeutic drugs and medical skin care products which are characterized by exceptional cosmetic properties.

hyliQTM products do not require skin irritating excipients such as preservatives or penetration enhancers.

  • technology
  • technology

How it works

Proprietary hyliQTM carrier molecules transport solubilized active ingredients through the stratum corneum, preferably into the epidermis, into glands, or into hair follicles. By selection of specific carrier molecules, we can customize the properties of our drug products, enhancing targeted penetration into the skin tissues, increasing efficacy and reducing unwanted side effects.

dermaliq skin
hyliQTM – drug candidates

full dose is absorbed into skin and glands

Stratum Corneum

Epidermis

Dermis

Subcutaneous Tissue

Stratum Corneum

Epidermis

Dermis

Subcutaneous Tissue

Our Pipeline

Our goal is to establish a comprehensive pipeline of next-generation topical drugs and medical skin care products based on our proprietary hyliQTM technology.

DLQ01
  • Androgenetic Alopecia
    DLQ01 is a liquid topical with a prostaglandin (PG) F2alpha analog developed to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern baldness. We plan to initiate a Phase 1b/2a safety and efficacy trial in men with androgenic alopecia in Q4 2022.
Pre­clinical Phase 1 Phase 2a Phase 2b Phase 3
  • Androgenetic Alopecia
    DLQ01 is a liquid topical with a prostaglandin (PG) F2alpha analog developed to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern baldness. We plan to initiate a Phase 1b/2a safety and efficacy trial in men with androgenic alopecia in Q4 2022.

DLQ01

DLQ02
  • Plaque Psoriasis
    DLQ02 is a liquid topical, calcineurin inhibitor with anti-inflammatory and immunomodulating properties, developed for the treatment of Psoriasis. There remains an unmet need for topical therapies, particularly for localized lesions only affecting limited body surface areas, which are usually not eligible for systemic treatments. DLQ02 has the potential to provide a highly effective and safe treatment option.

    The randomized, single-center, double-blind, vehicle-controlled Phase 1b/2a trial was started in July 2022 at the Centre of Human Disease Research (CHDR), Leiden, The Netherlands, and is designed to evaluate the safety and efficacy profile of two dose strengths of DLQ02 and its vehicle in patients diagnosed with mild to moderate plaque psoriasis. A targeted total of 36 patients, 12 per treatment group, will be enrolled. Trial completion is expected in Q2 2023.
Pre­clinical Phase 1 Phase 2a Phase 2b Phase 3
  • Plaque Psoriasis
    DLQ02 is a liquid topical, calcineurin inhibitor with anti-inflammatory and immunomodulating properties, developed for the treatment of Psoriasis. There remains an unmet need for topical therapies, particularly for localized lesions only affecting limited body surface areas, which are usually not eligible for systemic treatments. DLQ02 has the potential to provide a highly effective and safe treatment option.

    The randomized, single-center, double-blind, vehicle-controlled Phase 1b/2a trial was started in July 2022 at the Centre of Human Disease Research (CHDR), Leiden, The Netherlands, and is designed to evaluate the safety and efficacy profile of two dose strengths of DLQ02 and its vehicle in patients diagnosed with mild to moderate plaque psoriasis. A targeted total of 36 patients, 12 per treatment group, will be enrolled. Trial completion is expected in Q2 2023.

DLQ02

DLQ03
  • Bacterial soft tissue and skin infections
    DLQ03 is a liquid topical broad-spectrum antibiotic drug candidate designed for treatment of Bacterial skin and soft tissue infections, SSTIs are frequent and cases involving antibiotic resistant strains can be difficult to treat and even life-threatening. DLQ03 has the potential to provide a highly effective and safe treatment option.

    The randomized, single-center, double-blind, vehicle-controlled Phase 1b/2a trial was started in August 2022 at the Centre of Human Disease Research (CHDR), Leiden, The Netherlands, and is designed to evaluate the safety and efficacy profile of two dose strengths of DLQ03 and its vehicle in Atopic Dermatitis patients with a secondary Staph. Aureus infection. A total of 27 patients, 9 per treatment group, will be enrolled.

    Trial completion is expected in Q2 2023.
Pre­clinical Phase 1 Phase 2a Phase 2b Phase 3
  • Bacterial soft tissue and skin infections
    DLQ03 is a liquid topical broad-spectrum antibiotic drug candidate designed for treatment of Bacterial skin and soft tissue infections, SSTIs are frequent and cases involving antibiotic resistant strains can be difficult to treat and even life-threatening. DLQ03 has the potential to provide a highly effective and safe treatment option.

    The randomized, single-center, double-blind, vehicle-controlled Phase 1b/2a trial was started in August 2022 at the Centre of Human Disease Research (CHDR), Leiden, The Netherlands, and is designed to evaluate the safety and efficacy profile of two dose strengths of DLQ03 and its vehicle in Atopic Dermatitis patients with a secondary Staph. Aureus infection. A total of 27 patients, 9 per treatment group, will be enrolled.

    Trial completion is expected in Q2 2023.

DLQ03

Our Team

Management and Board of Directors

Frank Löscher, PhD

CEO, President & Co-Founder Dermaliq Therapeutics Inc.

Director

Oliver Schlüter, PhD

CFO & Co-Founder Dermaliq Therapeutics Inc.

Director (Chair)

Betsy Hughes-Formella, PhD

CSO & Co-Founder Dermaliq Therapeutics Inc.

Karen Liu, PhD

Founding partner 3E Bioventures Capital

Director

Christian Roesky, PhD

CEO Novaliq GmbH

Director

Scientific and Medical Advisory Board

Gordon J. Dow, Pharm.D.

Founder and former CTO/CEO Dow Pharmaceutical Sci. Inc.

Advisory Board

Xavier Yon

Former CEO Galderma  

Advisory Board

Michal E. Kuligowski, MD, PhD, MBA, iFAAD

VP, Dermatology, Clinical Research Group at Thermo Fischer Scientific, Inc.

Advisory Board

R. Todd Plott, M.D.

Chief Medical Officer Epiphany Dermatology

Advisory Board

Contact us

Head Office

Dermaliq Therapeutics, Inc.,
1201 North Market Street, Suite 111,
Wilmington, DE 19801, USA

German Subsidiary

Dermaliq Therapeutics GmbH
Im Neuenheimer Feld 515
69120 Heidelberg, Germany